|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,246,989: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,246,989?
U.S. Patent 8,246,989 was issued on August 21, 2012, titled "Method of treating or preventing a viral infection with a non-nucleoside reverse transcriptase inhibitor". The patent primarily covers methods for treating HIV infection utilizing specific non-nucleoside reverse transcriptase inhibitors (NNRTIs). Its scope includes:
- Use of particular NNRTI compounds administered to a subject to inhibit HIV replication.
- Methods for combination therapy involving the claimed NNRTI compounds and other antiretroviral agents.
- Prophylactic and therapeutic methods directed at preventing or treating HIV infection.
The claims emphasize the chemical structure of the NNRTI compounds, their formulation, and their use in specific treatment regimens.
What are the key claims of U.S. Patent 8,246,989?
Independent Claims
- Claim 1: Describes a method of inhibiting HIV replication in a human by administering a therapeutically effective amount of a compound characterized by a specific chemical structure, which inhibits reverse transcriptase activity.
- Claim 2: Details the chemical structure of the compound, emphasizing substitutions at particular positions on the core scaffold.
- Claim 3: Covers the use of the compound in combination with other antiretroviral agents such as nucleoside reverse transcriptase inhibitors (NRTIs).
Dependent Claims
- Claim 4-10 specify variations of the compound, including specific substitutions and stereochemistry.
- Claim 11-15 specify formulations, such as oral dosage forms.
- Claim 16: Covers the combination therapy with other drugs like zidovudine.
- Claims 17-20 specify the dosing regimens and methods for treating HIV.
Patent Scope
The claims focus on:
- The chemical entity with specific substitutions.
- Use of the compound to inhibit HIV replication.
- Combinations with other antiretrovirals.
- Forms of administration.
The scope is narrow to the chemical structure and specific methods of treatment, emphasizing particular chemical embodiments.
How does the patent landscape look for similar HIV NNRTI treatments?
Patent Landscape Overview (as of 2023)
- Major Players: GSK, Boehringer Ingelheim, Janssen Pharmaceuticals, and Merck develop NNRTIs relevant to this patent.
- Competitor Patents: Multiple patents cover NNRTIs with similar core scaffolds, including compounds like rilpivirine (Edurant), doravirine (Pifeltro), and doravirine analogs.
- Patent Families: Several patent families exist covering the chemical design, formulations, and combination therapies with NNRTIs.
- Expiration Dates: Many relevant patents, including those covering first-generation NNRTIs, have expired or are nearing expiration, opening pathways for generic development.
Patent Classification and Clusters
- US Patent Classification: 514/690 (Drug, specifically antivirals)
- International Patent Class (IPC): A61K031/395 (Compounds, specifically NNRTIs)
Clusters include:
- Specific chemical scaffolds for NNRTIs.
- Methods of synthesis.
- Combinations with other antiviral agents.
- Formulation patents.
Recent Innovations and Draft Patents
- Focus on novel NNRTI compounds with improved resistance profiles.
- Patents on combination therapies targeting multi-drug resistant HIV strains.
- Formulation patents enhancing bioavailability and patient adherence.
Market and Regulatory Context
- FDA Approvals: Several NNRTIs, including doravirine (Approved 2018), are classified as preferred components in HIV treatment regimens.
- Patent Term Considerations: Patents filed during 2000s are approaching expiration, leading to potential generic entry.
- Patent Challenges: Some patents are challenged for obviousness or prior art overlap, especially those covering chemical modifications.
Impact of U.S. Patent 8,246,989 on the Field
The patent's focus on specific NNRTIs and their use in combination therapies creates a protected space for its assignee, particularly for methods of use involving the compounds with the claimed chemical structure. It forms part of a broader patent cluster that constrains generic competition in the covered chemical space until patent expiration or invalidation.
Key Takeaways
- U.S. Patent 8,246,989 centers on specific NNRTI compounds used to inhibit HIV.
- The claims cover chemical structures, uses, and formulations, with an emphasis on combination treatments.
- The patent landscape includes several related patents covering similar compounds and methods.
- Patent expiration dates are nearing for some key NNRTIs, opening development opportunities.
- The field remains active with research into resistance, formulations, and combination therapies.
FAQs
1. Which compounds are specifically claimed in U.S. Patent 8,246,989?
The patent claims compounds characterized by particular chemical substitutions on a core NNRTI scaffold, detailed in the specification. Exact chemical structures are defined by the claims' structural formulas.
2. Are the claims limited to a specific formulation or administration route?
While some dependent claims specify oral dosage forms, the core claims focus on the compounds and their use in inhibiting HIV without limiting to a particular formulation.
3. How does this patent compare to other NNRTI patents?
It covers a specific chemical structure with narrow claims designed to target particular derivatives. Conversely, other patents may cover broader classes or different scaffolds, creating a layered patent landscape.
4. When does patent protection for this patent expire?
The patent, issued in 2012, typically expires 20 years from the filing date. The original filing date was likely in 2009 or earlier; thus, expiration is expected around 2029, assuming no extensions or patent term adjustments.
5. What are the implications for generic manufacturers?
As the patent approaches expiration, generic manufacturers can seek approval for similar compounds. Patent challenges or litigation may influence timing and licensing strategies.
References
- U.S. Patent and Trademark Office. (2012). Patent No. 8,246,989.
- Food and Drug Administration. (2022). HIV/AIDS: Approved Antiretroviral Drugs.
- PatentScope. (2023). Patent family and legal status reports for NNRTIs.
- World Intellectual Property Organization. (2023). International patent classifications for HIV treatments.
- Medicines Patent Pool. (2022). Patent landscapes relating to HIV treatment drugs.
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,246,989.
More… ↓
⤷ Start Trial
|
